

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,282 10/13/2005		Norito Doi	Q87437	5063
23373	7590 03/28/2006	EXAMINER		
	MION, PLLC SYLVANIA AVENUE, N	KRUER, KEVIN R		
SUITE 800	TEVANIA AVENOE, N.	ART UNIT	PAPER NUMBER	
WASHINGT	ON, DC 20037		1773	

DATE MAILED: 03/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

M

**			Application	n No.	Applicant(s)	·			
	200 A 45 Common.		10/531,282	2	DOI ET AL.				
	Office Action Summary		Examiner		Art Unit				
			Kevin R. Kr	1	1773				
Period fo	The MAILING DATE of this commun or Reply	iication app	ears on the	cover sheet with the c	orrespondence ad	ddress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
1)	Responsive to communication(s) file	ed on	_						
	This action is FINAL . 2b)⊠ This action is non-final.								
,—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is								
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	ion of Claims								
4)⊠	☑ Claim(s) <u>1-7</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
	Claim(s) is/are allowed.								
6)⊠	Claim(s) <u>1-7</u> is/are rejected.								
· · · · · · · · · · · · · · · · · · ·	Claim(s) is/are objected to.								
8)[8) Claim(s) are subject to restriction and/or election requirement.								
Applicati	on Papers		•						
9)[The specification is objected to by th	e Examiner	r.						
	The drawing(s) filed on is/are:			objected to by the E	Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
	The oath or declaration is objected to								
Priority u	ınder 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
Attachment	• •								
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (P	2TO 048)	,	 Interview Summary (Paper No(s)/Mail Date 					
3) 🔀 Inform	nation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date <u>4/14/05</u> .	PTO/SB/08)			formal Patent Application (PTO-152)				

Application/Control Number: 10/531,282 Page 2

Art Unit: 1773

DETAILED ACTION

Priority

1. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Information Disclosure Statement

2. The information disclosure statement filed April 14, 2005 has been fully considered. An initialed copy of said IDS is enclosed herein.

Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims 1-4, 6 and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kameda et al (US 3,988,392) in view of JP10-306192 (herein referred to as Tadokoro).

Kameda teaches a polymer composition consisting of 95-50wt% methyl methacrylate homopolymer or copolymer and 5-50wt% of a crosslinked elastomer. The methyl methacrylate polymer may comprise up to 20% of at least on copolymerizable vinyl or vinylidene copolymer (col 2, lines 12+). The elastomer is obtained by copolymerizing a mixture of alkyl acrylate, allyl acrylate, and/or allyl methacrylate, and benzyl acrylate. Said elastomer is graft polymerized with methyl methacrylate (abstract) in amount of 10-100pbw of the weight to the crosslinked elastomer (col 6, lines 40+).

Art Unit: 1773

The elastomer has a particle size of 500-25000angstrom (col 2, lines 26+) and has a crosslinking agent content of 0.5-5pbw (col 3, lines 48+). The composition may be used alone to make a film or utilized in a laminate (col 8, lines 4+).

Kameda does not explicitly state the claimed limitation (d). However, Kameda does teach that the elastomer should have a particle size of 500-2500A and a crosslinking agent content of 0.5-5pbw. Said teachings equate to a crosslinking agent content equal to 0.002d-0.1d, wherein d is the average particle size of the elastomer. Furthermore, Kameda teaches the crosslinking content should be controlled such that the elastomer's degree of the swelling is 3-20 and the gel content is not less than 80% (col 3, lines 68+). Thus, it would have been obvious to one of ordinary skill in the art to optimize the crosslinking content of the elastomer taught in Kameda in order to control its degree of swelling and gel content. By doing so, the skilled artisan can control the processability, luster, transparency, and impact resistance of the composition. The examiner notes the claimed limitation d will also be optimized as the crosslinking content of the elastomer is optimized.

Kameda does not teach the composition should have a reduced viscosity of methyl ethyl ketone soluble matter in the resin composition of 0.2-0.8dl/g. However, Tadokoro teaches a composition comprising an acrylic matrix and a multi-layered acrylic elastomeric graft polymer (abstract). Tadorko teaches the reduced viscosity of said composition should be controlled in order to control the processability of said composition (0001-0004). Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to optimize the reduced viscosity of

Art Unit: 1773

the resin composition taught in Kameda. The motivation for doing so would have been to control the processability of said composition.

5. Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kameda et al (US 3,988,392) in view of JP10-306192, as applied to claims above, and further in view of WO02/085620A1 (herein referred to as Nishimura).

Kameda is relied upon as above, but does not teach the graft should comprise two stages wherein the outer stage comprises the claimed methyl methacrylate content. However, Nishimura teaches a resin composition comprising a methyl methacrylate © polymer and an impact modifying multiplayer graft polymer. The graft polymer comprises a rubber base and a two-stage polymerization to form the graft (page 6, last paragraph). The rubber base may comprise an acrylic rubber. The first stage is not limited. The second stage comprises methyl methacrylate and 1-40wt% of a reactive monomer. The presence of said reactive monomer results in a blend that is processable and that exhibits excellent impact resistance (page 2, first paragraph). Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to add a second stage to the graft copolymer taught in Kameda, wherein that second stage comprises methyl methacrylate and 1-40wt% of a reactive monomer. The motivation for doing so would have been to obtain a blend that exhibits impact resistance and processability. Furthermore, it would have been obvious to optimize the reactive monomer content of said second stage of the graft in order to control the composition's impact resistance, appearance, and processability.

Application/Control Number: 10/531,282

Art Unit: 1773

Conclusion

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin R. Kruer whose telephone number is 571-272-

1510. The examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Carol Chaney can be reached on 571-272-1284. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kevin R. Kruer

R-RX

Patent Examiner-Art Unit 1773